» Articles » PMID: 36007855

Peroxisome Proliferator-activated Receptor Gamma Agonist ELB00824 Suppresses Oxaliplatin-induced Pain, Neuronal Hypersensitivity, and Oxidative Stress

Overview
Specialties Neurology
Pharmacology
Date 2022 Aug 25
PMID 36007855
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy-induced neuropathic pain (CINP) is a debilitating and difficult-to-treat side effect of chemotherapeutic drugs. CINP is marked with oxidative stress and neuronal hypersensitivities. The peroxisome proliferator-activated receptor gamma (PPARγ) is a transcription factor that regulates genes involved in oxidative stress and inflammation. We hypothesize that PPARγ agonists are protective against CIPN by reducing oxidative stress and inhibiting neuronal hypersensitivities. To test our hypothesis, acute or chronic CIPN was introduced by short or long-term treatment of oxaliplatin in BALB/c mice. CIPN mice were treated with either a novel blood-brain barrier (BBB) penetrable PPARγ agonist ELB00824, or a BBB non-penetrable PPARγ agonist pioglitazone, or vehicle. Cold allodynia, mechanical allodynia, motor coordination, sedation and addiction were measured with dry ice, von Frey filaments, beam-walking tests, and conditioned place preference, respectively. Oxidative stress was accessed by measuring byproducts of protein oxidation (carbonyl and 3-Nitrotyrosine) and lipid peroxidation [Thiobarbituric acid reactive substances (TBARS)], as wells as gene expression of Cat, Sod2, Ppargc1a. The effects of ELB00824 on nociceptor excitability were measured using whole-cell electrophysiology of isolated dorsal root ganglion neurons. Preemptive ELB00824, but not pioglitazone, reduced oxaliplatin-induced cold and mechanical allodynia and oxidative stress. ELB0824 suppressed oxaliplatin-induced firing in IB4 neurons. ELB00824 did not cause motor discoordination or sedation/addiction or reduce the antineoplastic activity of oxaliplatin (measured with an MTS-based cell proliferation assay) in a human colon cancer cell line (HCT116) and a human oral cancer cell line (HSC-3). Our results demonstrated that ELB00824 prevents oxaliplatin-induced pain, likely via inhibiting neuronal hypersensitivities and oxidative stress.

Citing Articles

Regulatory role of PPAR in colorectal cancer.

Wang C, Lv T, Jin B, Li Y, Fan Z Cell Death Discov. 2025; 11(1):28.

PMID: 39875357 PMC: 11775197. DOI: 10.1038/s41420-025-02313-2.


TLR-4: a promising target for chemotherapy-induced peripheral neuropathy.

Babu N, Gadepalli A, Akhilesh , Sharma D, Singh A, Chouhan D Mol Biol Rep. 2024; 51(1):1099.

PMID: 39466456 DOI: 10.1007/s11033-024-10038-1.


Suppression of the postprandial hyperglycemia in patients with type 2 diabetes by a raw medicinal herb powder is weakened when consumed in ordinary hard gelatin capsules: A randomized crossover clinical trial.

Moreira F, Reis C, Gallassi A, Moreira D, Welker A PLoS One. 2024; 19(10):e0311501.

PMID: 39383145 PMC: 11463819. DOI: 10.1371/journal.pone.0311501.


Characterization of pain-related behaviors and gene expression profiling of peripheral sensory ganglia in a mouse model of acute ankle sprain.

Pan Y, Hu Q, Yang Y, Nie H, Yin C, Wei H Front Behav Neurosci. 2023; 17:1189489.

PMID: 37304762 PMC: 10248128. DOI: 10.3389/fnbeh.2023.1189489.

References
1.
Alsalem M, Haddad M, Aldossary S, Kalbouneh H, Azab B, Dweik A . Effects of Dual Peroxisome Proliferator-Activated Receptors and Activation in Two Rat Models of Neuropathic Pain. PPAR Res. 2019; 2019:2630232. PMC: 6500665. DOI: 10.1155/2019/2630232. View

2.
Brenner D, Golden J, Gereau 4th R . A novel behavioral assay for measuring cold sensation in mice. PLoS One. 2012; 7(6):e39765. PMC: 3382130. DOI: 10.1371/journal.pone.0039765. View

3.
Pires D, Blundell T, Ascher D . pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015; 58(9):4066-72. PMC: 4434528. DOI: 10.1021/acs.jmedchem.5b00104. View

4.
Ma J, Kavelaars A, Dougherty P, Heijnen C . Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. Cancer. 2018; 124(11):2289-2298. PMC: 5991994. DOI: 10.1002/cncr.31248. View

5.
Portilla D, Dai G, McClure T, Bates L, Kurten R, Megyesi J . Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int. 2002; 62(4):1208-18. DOI: 10.1111/j.1523-1755.2002.kid553.x. View